Cargando…
Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) contributes decisively to the development of cardiovascular disease (CVD). In the LYNX registry we determined the rate of achievement of the target value of LDL-C, the use of lipid-lowering therapy (LLT) and the predictive factors of not reachi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430891/ https://www.ncbi.nlm.nih.gov/pubmed/32849966 http://dx.doi.org/10.14740/cr1079 |
_version_ | 1783571503290253312 |
---|---|
author | Gomez-Barrado, Jose Javier Gomez-Turegano, Paula Ortiz-Cortes, Carolina Vega-Fernandez, Jorge Gomez-Turegano, Marta Garciperez de Vargas, Francisco Javier Lezcano Gort, Luis Enrique Kounka, Zineb Roque Rodriguez, Benjamin Chipayo Gonzales, David Perez-Espejo, Paloma Fernandez-Chamorro, Ana Isabel Beltran Moreno, Maria Romero Castro, Maria Jose Mogollon Jimenez, Maria Victoria Marcos Gomez, Gonzalo Porras Ramos, Yolanda |
author_facet | Gomez-Barrado, Jose Javier Gomez-Turegano, Paula Ortiz-Cortes, Carolina Vega-Fernandez, Jorge Gomez-Turegano, Marta Garciperez de Vargas, Francisco Javier Lezcano Gort, Luis Enrique Kounka, Zineb Roque Rodriguez, Benjamin Chipayo Gonzales, David Perez-Espejo, Paloma Fernandez-Chamorro, Ana Isabel Beltran Moreno, Maria Romero Castro, Maria Jose Mogollon Jimenez, Maria Victoria Marcos Gomez, Gonzalo Porras Ramos, Yolanda |
author_sort | Gomez-Barrado, Jose Javier |
collection | PubMed |
description | BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) contributes decisively to the development of cardiovascular disease (CVD). In the LYNX registry we determined the rate of achievement of the target value of LDL-C, the use of lipid-lowering therapy (LLT) and the predictive factors of not reaching the target in patients with stable coronary heart disease (CHD). METHODS: LYNX included consecutive patients with stable CHD treated at the University Hospital of Caceres, Extremadura (Spain) from September 2016 to September 2018, and those who must have an LDL-C target below 70 mg/dL according to the European Society of Cardiology (ESC) 2016 guidelines. The variables independently associated with the breach of the LDL-C objective were evaluated by multivariable logistic regression. RESULTS: A total of 674 patients with stable CHD were included. The average LDL-C levels were 68.3 ± 24.5 mg/dL, with 56.7% showing a level below 70 mg/dL. LLT was used by 96.7% of patients, 71.7% were treated with high-powered statins and 30.1% with ezetimibe. The risk of not reaching the target value of LDL-C was higher in women, in active smokers, and in those who had multivessel CHD or had atrial fibrillation. Patients with diabetes mellitus, those who took potent statins or co-administration treatment with ezetimibe were more likely to reach the target level of LDL-C. CONCLUSIONS: The treatment of dyslipidemia in patients with chronic CHD remains suboptimal; however, an increasing number of very high-risk patients achieve the LDL-C objective, although there is still enormous potential to improve cardiovascular outcome through the use of more intensive LLT. |
format | Online Article Text |
id | pubmed-7430891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74308912020-08-25 Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry Gomez-Barrado, Jose Javier Gomez-Turegano, Paula Ortiz-Cortes, Carolina Vega-Fernandez, Jorge Gomez-Turegano, Marta Garciperez de Vargas, Francisco Javier Lezcano Gort, Luis Enrique Kounka, Zineb Roque Rodriguez, Benjamin Chipayo Gonzales, David Perez-Espejo, Paloma Fernandez-Chamorro, Ana Isabel Beltran Moreno, Maria Romero Castro, Maria Jose Mogollon Jimenez, Maria Victoria Marcos Gomez, Gonzalo Porras Ramos, Yolanda Cardiol Res Original Article BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) contributes decisively to the development of cardiovascular disease (CVD). In the LYNX registry we determined the rate of achievement of the target value of LDL-C, the use of lipid-lowering therapy (LLT) and the predictive factors of not reaching the target in patients with stable coronary heart disease (CHD). METHODS: LYNX included consecutive patients with stable CHD treated at the University Hospital of Caceres, Extremadura (Spain) from September 2016 to September 2018, and those who must have an LDL-C target below 70 mg/dL according to the European Society of Cardiology (ESC) 2016 guidelines. The variables independently associated with the breach of the LDL-C objective were evaluated by multivariable logistic regression. RESULTS: A total of 674 patients with stable CHD were included. The average LDL-C levels were 68.3 ± 24.5 mg/dL, with 56.7% showing a level below 70 mg/dL. LLT was used by 96.7% of patients, 71.7% were treated with high-powered statins and 30.1% with ezetimibe. The risk of not reaching the target value of LDL-C was higher in women, in active smokers, and in those who had multivessel CHD or had atrial fibrillation. Patients with diabetes mellitus, those who took potent statins or co-administration treatment with ezetimibe were more likely to reach the target level of LDL-C. CONCLUSIONS: The treatment of dyslipidemia in patients with chronic CHD remains suboptimal; however, an increasing number of very high-risk patients achieve the LDL-C objective, although there is still enormous potential to improve cardiovascular outcome through the use of more intensive LLT. Elmer Press 2020-10 2020-08-01 /pmc/articles/PMC7430891/ /pubmed/32849966 http://dx.doi.org/10.14740/cr1079 Text en Copyright 2020, Gomez-Barrado et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Gomez-Barrado, Jose Javier Gomez-Turegano, Paula Ortiz-Cortes, Carolina Vega-Fernandez, Jorge Gomez-Turegano, Marta Garciperez de Vargas, Francisco Javier Lezcano Gort, Luis Enrique Kounka, Zineb Roque Rodriguez, Benjamin Chipayo Gonzales, David Perez-Espejo, Paloma Fernandez-Chamorro, Ana Isabel Beltran Moreno, Maria Romero Castro, Maria Jose Mogollon Jimenez, Maria Victoria Marcos Gomez, Gonzalo Porras Ramos, Yolanda Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry |
title | Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry |
title_full | Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry |
title_fullStr | Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry |
title_full_unstemmed | Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry |
title_short | Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry |
title_sort | low-density lipoprotein cholesterol targets in patients with coronary heart disease in extremadura (spain): lynx registry |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430891/ https://www.ncbi.nlm.nih.gov/pubmed/32849966 http://dx.doi.org/10.14740/cr1079 |
work_keys_str_mv | AT gomezbarradojosejavier lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT gomeztureganopaula lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT ortizcortescarolina lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT vegafernandezjorge lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT gomeztureganomarta lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT garciperezdevargasfranciscojavier lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT lezcanogortluisenrique lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT kounkazineb lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT roquerodriguezbenjamin lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT chipayogonzalesdavid lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT perezespejopaloma lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT fernandezchamorroanaisabel lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT beltranmorenomaria lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT romerocastromariajose lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT mogollonjimenezmariavictoria lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT marcosgomezgonzalo lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry AT porrasramosyolanda lowdensitylipoproteincholesteroltargetsinpatientswithcoronaryheartdiseaseinextremaduraspainlynxregistry |